One drug used alone to help hold remission in brain lymphoma
Original title: IMiD-based monotherapy for maintenance of remission in primary CNS lymphoma: a single-center experience.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is one center's report on care already given, not a trial.
The short version
One center reported on using a single drug to help keep brain lymphoma in remission.
What was studied. This report comes from a single center. It covers using one drug by itself after primary CNS lymphoma, a lymphoma that starts in the brain and spinal cord, went into remission.
What they found. No results are available for this item. The study summary was not provided, so there are no numbers to share. We cannot say what the center found.
What this means, and what it doesn't
What it could mean: There is nothing here for a patient to act on today. If you are in remission, ask your care team what they do to help hold it.
What it doesn't mean: This does not mean the drug works or is proven. It is one center's report on patients it already treated, not a large trial. No results are shown here at all. It is not a cure, and it does not change everyday care.
Source: PubMed, August 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.